KALV KalVista Pharmaceuticals
- 12.600
- +0.110+0.88%
KalVista Pharmaceuticals News
When Will KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Breakeven?
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. KalVista Pharmaceuticals, Inc., a clinic
KalVista Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
KalVista Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The KalVista Pharma (KALV.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $24.00 to $20.00.
HC Wainwright & Co. : The KalVista Pharma (KALV.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $24.00 to $20.00.
HC Wainwright & Co. Maintains Buy on KalVista Pharma, Lowers Price Target to $20
HC Wainwright & Co. analyst Andrew Fein maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $24 to $20.
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals: A Strong Buy on Strategic Growth and Promising Sebetralstat Prospects
Kalvista Pharmaceuticals Announced Its Strategic Plans For Fiscal Year 2025, Beginning May 1, Including For Sebetralstat, The Company's Investigational Novel, Oral Plasma Kallikrein Inhibitor For The On-demand Treatment Of Hereditary Angioedema
Kalvista Pharmaceuticals Announced Its Strategic Plans For Fiscal Year 2025, Beginning May 1, Including For Sebetralstat, The Company's Investigational Novel, Oral Plasma Kallikrein Inhibitor For The
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
- Regulatory filings planned for US, EU, UK and Japan to enable multiple 2025 commercial launches – - Development strategy refined for oral Factor XIIa program – - Organizational focus to drive result
KalVista Pharmaceuticals Welcomes New Board Member
KalVista Pharmaceuticals: Fairey Was Most Recently Chief Comml Officer at MyoKardia >KALV
KalVista Pharmaceuticals: Fairey Was Most Recently Chief Comml Officer at MyoKardia >KALV
KalVista Pharmaceuticals Appoints William C. Fairey to Bd of Directors >KALV
KalVista Pharmaceuticals Appoints William C. Fairey to Bd of Directors >KALV
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 22, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, an
Needham: Reiterates KalVista Pharma (KALV.US) rating and adjusted from buy to buy rating, target price is $35.00.
Needham: Reiterates KalVista Pharma (KALV.US) rating and adjusted from buy to buy rating, target price is $35.00.
Needham Reiterates Buy on KalVista Pharma, Maintains $35 Price Target
Needham analyst Serge Belanger reiterates KalVista Pharma with a Buy and maintains $35 price target.
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), KalVista Pharmaceuticals (KALV) and PTC Therapeutics (PTCT)
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors g
HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $24 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma with a Buy and maintains $24 price target.
KalVista Pharmaceuticals Announced The UK Medicines And Healthcare Products Regulatory Agency Has Awarded The Promising Innovative Medicine Designation For Sebetralstat For On-demand Treatment Of Hereditary Angioedema
KalVista Pharmaceuticals Announced The UK Medicines And Healthcare Products Regulatory Agency Has Awarded The Promising Innovative Medicine Designation For Sebetralstat For On-demand Treatment Of Here
Analysis
Price Target
No Data
